Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micardis Promotion Cited By FDA For Superiority Claims Over Norvasc, Diovan

This article was originally published in The Pink Sheet Daily

Executive Summary

References included in a Boehringer Ingelheim sales aid for Micardis do not provide sufficient evidence or clinical experience to support the superiority claims, an FDA ad division "untitled" letter states. The agency also cites the sales aid for including unsubstantiated efficacy claims and omitting risk information.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS058271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel